Vyome Reports Significant Reduction in Q3 2026 Loss Per Share and Advances Lead VT-1953 Program

Vyome Holdings Reports Third-Quarter 2026 Financial Results, Advances VT-1953 Development and Strengthens Ophthalmology Pipeline

Vyome Holdings, a clinical-stage biopharmaceutical company focused on developing treatments for immuno-inflammatory and rare diseases, has announced its financial results for the third quarter ended September 30, 2026, along with an update on its corporate activities and clinical development programs. During the quarter, the company continued prioritizing the advancement of its lead investigational candidate, VT-1953, while maintaining financial discipline and progressing development activities across its broader pipeline.

Vyome’s third-quarter business activities primarily focused on regulatory preparation, product development, chemistry, manufacturing and controls (CMC), and clinical development planning for VT-1953. The investigational topical gel is being developed to address the signs and symptoms of malignant fungating wounds, a serious condition that can cause substantial discomfort and negatively affect patients’ quality of life.

The company also continued formulation and CMC development activities for VT-1908, its investigational topical ophthalmic program targeting anterior uveitis. In addition, Vyome reported progress in its intellectual property portfolio, following the issuance of a Notice of Allowance by the United States Patent and Trademark Office (USPTO) for patent claims covering formulations and methods of use associated with VT-1908.

As of September 30, 2026, Vyome reported approximately $7.0 million in cash and cash equivalents, providing financial resources to support its ongoing development priorities and corporate activities.

Company Prioritizes Lead Program VT-1953

Krishna Gupta, Chairman of Vyome Holdings, stated that the company continued to concentrate its resources on advancing VT-1953 during the third quarter while maintaining a disciplined approach to financial management and selectively progressing other pipeline activities.

According to Gupta, Vyome ended September 2026 with approximately $7.0 million in cash and cash equivalents. The company’s primary focus remains on executing its defined development priorities, allocating capital carefully and supporting the advancement of its investigational programs.

He emphasized that the company intends to maintain a focused development strategy while evaluating opportunities across its immuno-inflammatory disease portfolio.

Venkat Nelabhotla, President and Chief Executive Officer of Vyome Holdings, highlighted the company’s continued efforts to advance VT-1953 through product development, regulatory preparation and manufacturing planning.

During the quarter, Vyome continued activities related to product development, CMC preparation and clinical development planning. The company also conducted preliminary work with prospective Good Manufacturing Practice (GMP) manufacturing partners to prepare for future development and manufacturing requirements.

Following written feedback from the U.S. Food and Drug Administration (FDA) on its pre-investigational new drug (pre-IND) briefing package for VT-1953, Vyome continued compiling the scientific, CMC and clinical information required to support further regulatory discussions.

The company is preparing for a planned Type C meeting with the FDA to discuss the agency’s feedback and determine the appropriate next steps before moving forward with its proposed clinical development program.

Nelabhotla also noted that Vyome is reviewing additional information and clarification requested by the FDA regarding its Orphan Drug Designation application for VT-1953. The company is preparing a response and evaluating whether an amendment to the application will be necessary.

Alongside its lead program, Vyome continued formulation and CMC activities for VT-1908, its investigational ophthalmic candidate. The company remains focused on advancing its research programs and evaluating selective opportunities in immuno-inflammatory diseases while making development and investment decisions based on available scientific and clinical evidence.

VT-1953 Regulatory Development and FDA Engagement

VT-1953 remains Vyome’s primary development priority. The investigational topical gel is being developed for the treatment of signs and symptoms associated with malignant fungating wounds.

Malignant fungating wounds are complications that can occur in patients with advanced cancers when tumors invade the skin and underlying tissues. These wounds can be associated with several challenging symptoms, including persistent malodor, pain, discharge, bleeding and tissue breakdown.

Malodor can be particularly distressing for patients and caregivers, affecting daily activities, emotional well-being and social interactions. Existing management approaches may involve wound care, dressings and treatments intended to control individual symptoms, highlighting the need for additional therapeutic options.

Vyome is developing VT-1953 as a potential treatment approach intended to address important symptoms associated with these wounds.

During the third quarter, the company continued incorporating the FDA’s written feedback following its review of the pre-IND briefing package. The regulatory feedback is being used to guide the preparation of additional scientific, clinical and CMC documentation.

These activities are intended to support a Type C meeting with the FDA, through which Vyome plans to discuss the development pathway and regulatory considerations for VT-1953.

The planned meeting represents an important step in the company’s regulatory strategy. Discussions with the agency are expected to help clarify development expectations and identify the information required to support the proposed clinical program.

In parallel, Vyome continued product formulation and manufacturing-related activities. The company is conducting preparatory work with prospective GMP manufacturing partners to support the potential production requirements associated with future clinical development.

The CMC program is an important component of the development process because it addresses the formulation, manufacturing processes, quality controls and product consistency required for clinical investigations and eventual regulatory evaluation.

Vyome’s ongoing efforts are intended to establish the necessary development and manufacturing foundation before advancing VT-1953 into its proposed clinical program.

FDA Requests Additional Information for Orphan Drug Designation Application

Vyome also provided an update on the Orphan Drug Designation application submitted for VT-1953.

During the reporting period, the company received correspondence from the FDA requesting additional information and clarification regarding the application. Vyome is reviewing the agency’s questions and preparing the necessary response, including any required amendment.

Orphan Drug Designation is an important regulatory pathway intended to encourage the development of treatments for rare diseases and conditions affecting relatively small patient populations.

In the United States, qualifying orphan drug programs may receive certain development incentives and regulatory benefits intended to support research into conditions for which treatment options may be limited.

The FDA’s request for further information forms part of the ongoing application review process. Vyome’s response will address the additional details requested by the agency.

The company has not indicated that the designation has been granted and continues to work through the regulatory review process.

The progress of the application, together with the planned Type C meeting, represents an important part of Vyome’s broader regulatory strategy for VT-1953.

Previously Reported Positive Phase 2 Results for VT-1953

Vyome’s development strategy for VT-1953 is supported by previously reported findings from an investigator-initiated Phase 2 study.

According to the company, the study demonstrated positive and statistically significant improvements across several important symptom-related measures associated with malignant fungating wounds.

The reported improvements included:

  • Reduction in wound-associated malodor.
  • Improvement in the patient-reported impact of malodor on daily life.
  • Reduction in lesion-associated pain.

Importantly, the company reported that no treatment-emergent adverse events were observed in the investigator-initiated Phase 2 study.

These findings provide clinical evidence supporting further investigation of VT-1953 as a potential treatment for patients experiencing the challenging symptoms associated with malignant fungating wounds.

Malodor, pain and the broader impact of chronic wound symptoms can significantly affect patients’ daily functioning and quality of life. Therefore, treatments capable of improving these outcomes could address an important unmet medical need.

However, additional clinical studies will be required to further evaluate the safety, tolerability and efficacy of VT-1953 and establish its potential role in clinical practice.

Vyome’s current regulatory and development activities are intended to support the next stage of the program, with continued engagement with the FDA remaining a key priority.

VT-1908 Ophthalmic Program Advances With Patent Progress

In addition to VT-1953, Vyome continued advancing VT-1908, its investigational topical ophthalmic program being developed for anterior uveitis.

Anterior uveitis is an inflammatory condition affecting the front portion of the eye, particularly the iris and surrounding structures. The condition can cause eye pain, redness, light sensitivity and blurred vision. If inadequately managed, inflammation may lead to complications that affect visual function.

The development of new ophthalmic treatment options remains important for patients who experience recurrent or persistent inflammatory eye conditions.

During the third quarter, Vyome continued formulation development and CMC activities for VT-1908. The company also progressed GMP manufacturing planning to support the program’s future development requirements.

An important intellectual property milestone was achieved in October 2026, when the USPTO issued a Notice of Allowance for patent application claims covering formulations and methods of use associated with VT-1908.

The allowed claims relate to the formulations and methods underlying the investigational ophthalmic program.

The Notice of Allowance represents progress in protecting the intellectual property associated with VT-1908 and may help strengthen the company’s position as it continues developing the candidate.

Patent protection is an important consideration for biotechnology companies because it can support the long-term development and potential commercialization of proprietary therapeutic technologies.

Vyome’s continued formulation and manufacturing activities, together with the intellectual property progress, reflect its efforts to advance VT-1908 alongside its lead VT-1953 program.

Vyome Strengthens Financial Leadership and Corporate Expertise

Vyome also announced developments in its corporate leadership during the reporting period.

The company appointed Jerry Leonard as Chief Financial Officer, effective September 1, 2026. The appointment is intended to support the company’s financial management and corporate operations as it continues progressing its clinical-stage development programs.

Financial leadership remains particularly important for clinical-stage biotechnology companies, which must carefully manage research and development investments, regulatory expenses, manufacturing preparations and other operating requirements.

The appointment comes as Vyome continues emphasizing disciplined capital allocation and prioritizing its lead development candidate.

Additionally, Dr. Shiladitya Sengupta, co-founder and director of Vyome, was promoted to Professor of Medicine at Harvard Medical School in October 2026.

The academic promotion represents a professional milestone for Dr. Sengupta and highlights the scientific and medical expertise associated with the company’s founding leadership.

Vyome continues to rely on its scientific, clinical and corporate leadership to guide the advancement of its investigational programs and identify opportunities across immuno-inflammatory and rare disease conditions.

Third Quarter 2026 Financial Results

Vyome reported its financial results for the three and nine months ended September 30, 2026, reflecting changes in operating expenses, revenue and net losses compared with the corresponding periods in 2025.

Cash Position and Total Assets

As of September 30, 2026, Vyome reported cash and cash equivalents of $6,956,822, compared with $4,982,333 as of December 31, 2025.

The increase in cash and cash equivalents reflects the company’s reported financial position during the first nine months of 2026.

Total assets stood at $8,611,672 as of September 30, 2026.

Total stockholders’ equity was $6,545,927, compared with $3,762,017 as of December 31, 2025.

These figures provide an overview of the company’s financial position as it continues investing in product development, regulatory preparation and manufacturing-related activities.

Revenue Performance

For the third quarter ended September 30, 2026, Vyome generated revenue of $57,998, compared with $34,627 in the third quarter of 2025.

For the first nine months of 2026, revenue totaled $116,544, compared with $283,163 during the corresponding period in 2025.

The reported figures reflect the company’s revenue performance across the respective reporting periods.

Operating Expenses

Vyome reported total operating expenses of $1,047,943 for the third quarter of 2026.

These expenses included:

  • Research and development expenses of $409,831.
  • Selling, general and administrative expenses of $635,410.

In comparison, total operating expenses for the third quarter of 2025 were $8,592,360.

The prior-year quarter included $7,705,533 in merger-related transactional fees, $39,677 in research and development expenses and $844,344 in selling, general and administrative expenses.

The substantial reduction in operating expenses during the third quarter of 2026 was primarily influenced by the absence of the significant merger-related transactional expenses recorded in the corresponding 2025 period.

Research and development expenses increased compared with the prior-year quarter, reflecting the company’s ongoing investment in its development programs.

Net Loss and Loss Per Share

Vyome reported a net loss of $930,325 for the third quarter ended September 30, 2026, compared with a net loss of $8,595,300 in the third quarter of 2025.

The net loss attributable to the company’s owners was $885,408, equivalent to a loss of $0.13 per basic and diluted share.

For the corresponding quarter in 2025, the net loss attributable to owners was $8,433,811, representing a loss of $3.06 per basic and diluted share.

The reduction in reported loss per share should be considered in the context of substantial merger-related transactional expenses recorded in the prior-year period, as well as changes in the weighted-average number of shares outstanding.

For the nine months ended September 30, 2026, Vyome reported a total net loss of $2,635,529, compared with $9,198,033 for the same period in 2025.

The loss per basic and diluted share for the first nine months of 2026 was $0.37, compared with $9.82 in the corresponding period of the previous year.

The year-over-year improvement in reported net loss primarily reflects the lower expenses associated with the absence of the significant merger-related charges recorded in 2025.

Focus Remains on Development Execution and Capital Management

Vyome’s third-quarter results highlight the company’s continued transition toward advancing its clinical-stage pipeline while maintaining financial discipline.

The company is prioritizing VT-1953, with ongoing regulatory discussions, formulation development, CMC preparation and manufacturing planning expected to support its proposed clinical development pathway.

The planned Type C meeting with the FDA will be an important opportunity to discuss the agency’s feedback and clarify the next steps for the program. Meanwhile, the company is addressing the additional information requested for its Orphan Drug Designation application.

Vyome is also continuing to advance VT-1908 through formulation and manufacturing preparation, supported by the recent USPTO Notice of Allowance covering relevant patent claims.

With approximately $7.0 million in cash and cash equivalents at the end of September 2026, the company intends to maintain a focused approach to development spending and capital allocation.

Vyome stated that it will continue evaluating its investigational programs and selective opportunities within immuno-inflammatory diseases based on available scientific evidence and development priorities.

Complete financial results for the third quarter ended September 30, 2026, are available in the company’s Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (SEC).

The company’s progress across VT-1953 and VT-1908, together with its regulatory, intellectual property and financial updates, outlines its ongoing efforts to advance potential treatments for patients with significant unmet medical needs.

About Vyome Holdings, Inc.:

Vyome is building the world’s premier platform spanning the US-India innovation corridor. Vyome’s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter